OverviewSuggest Edit

BioPharmX Corporation is a specialty pharmaceutical company focused on utilizing proprietary drug delivery technologies to develop and commercialize novel prescription, over-the-counter and supplement products that address large markets in dermatology and women’s health. The Company’s objective is to develop products that treat health or age-related conditions that are not presently being addressed or treated at all or are currently treated with drug therapies or drug delivery approaches that are sub-optimal. BioPharmX has developed a product portfolio using its drug delivery technologies, including delivery mechanisms for antibiotics, biologic materials, and molecular iodine.

The Company currently has one marketed product, a VI2OLET iodine dietary supplement, two clinical‑stage product candidates, BPX01 and BPX03 and one development‑stage product candidate, BPX02. VI2OLET is a molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches, and swelling. BPX03 is a prescription drug version of the molecular iodine tablet for the treatment of moderate to severe, periodic breast pain associated with FBC and cyclic mastalgia. BPX01 is a hydrophilic, topical antibiotic gel for the treatment of acne vulgaris and BPX02 is an injectable product utilizing biologic materials for aesthetic dermatology applications.


TypePublic
Founded2011
HQMenlo Park, US
Websitebiopharmx.com

Latest Updates

Employees (est.) (Feb 2019)27(+35%)
Revenue (FY, 2019)$57 K(-21%)
Share Price (Mar 2019)$0.1 (+3%)

BioPharmX Office Locations

BioPharmX has an office in Menlo Park
Menlo Park, US (HQ)
1505 Adams Dr
Show all (1)
Report incorrect company information

BioPharmX Financials and Metrics

BioPharmX Revenue

BioPharmX 's revenue was reported to be $57 k in FY, 2019
USD

Revenue (FY, 2019)

57.0k

Gross profit (FY, 2019)

(26.0k)

Gross profit margin (FY, 2019), %

(45.6%)

EBIT (FY, 2019)

(16.5m)

Market capitalization (15-Mar-2019)

21.9m

Closing stock price (15-Mar-2019)

0.1

Cash (31-Jan-2019)

3.1m
BioPharmX 's current market capitalization is $21.9 m.
Annual
USDFY, 2013FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

64.0k100.0k73.0k57.0k

Cost of goods sold

237.0k516.0k250.0k83.0k

Gross profit

(173.0k)(416.0k)(177.0k)(26.0k)

Gross profit Margin, %

(270%)(416%)(242%)(46%)
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

5.0k20.0k33.0k19.0k33.0k19.0k17.0k18.0k18.0k24.0k10.0k

Cost of goods sold

10.0k19.0k20.0k17.0k28.0k11.0k9.0k8.0k7.0k13.0k60.0k

Gross profit

(5.0k)1.0k13.0k2.0k5.0k8.0k8.0k10.0k11.0k11.0k(50.0k)

Gross profit Margin, %

(100%)5%39%11%15%42%47%56%61%46%(500%)
Annual
USDFY, 2013FY, 2016FY, 2017FY, 2018FY, 2019

Cash

162.04.0m6.5m7.6m3.1m

Accounts Receivable

7.0k4.0k7.0k4.0k

Inventories

100.0k38.0k10.0k

Current Assets

39.0k4.4m6.8m8.0m3.4m
Quarterly
USDQ3, 2014Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

1.2m7.4m2.2m4.0m436.0k468.0k6.7m4.5m1.6m10.9m6.6m3.0m

Accounts Receivable

33.0k9.0k6.0k1.0k7.0k3.0k2.0k8.0k5.0k16.0k4.0k

Inventories

364.0k336.0k76.0k112.0k77.0k30.0k20.0k15.0k6.0k13.0k10.0k

Current Assets

1.5m8.2m2.8m4.4m1.0m1.3m7.0m5.0m2.2m11.3m7.3m3.6m
Annual
USDFY, 2013FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(52.3k)(15.6m)(18.4m)(16.6m)(17.3m)

Depreciation and Amortization

207.056.0k141.0k52.0k62.0k

Inventories

60.0k62.0k28.0k

Accounts Payable

446.0k625.0k774.0k(1.2m)(13.0k)
USDY, 2019

Financial Leverage

2.8 x
Show all financial metrics
Report incorrect company information

BioPharmX Online and Social Media Presence

Embed Graph
Report incorrect company information

BioPharmX News and Updates

BioPharmX to Participate in the 31st Annual ROTH Conference and the Oppenheimer 29th Annual Healthcare Conference

SAN JOSE, Calif., March 18, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced presentations at multiple upcoming investor conferences. President and CEO Dr....

Thinking about buying stock in Apple, BioPharmX, China Ceramics Co., Netflix or Weatherford International?

NEW YORK, Jan. 2, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, BPMX, CCCL, NFLX, and WFT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

BioPharmX Reports Third Quarter 2019 Financial Results

MENLO PARK, Calif., Dec. 6, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the quarter ended Oct. 31, 2018. During the quarter, newly...

BioPharmX Announces NYSE American Acceptance of Plan To Regain Listing Compliance

MENLO PARK, Calif., Nov. 16, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company developing products for the dermatology market, announced that on November 1, 2018, NYSE Regulation accepted the Company's plan to regain...

BioPharmX Receives Notice of Noncompliance from NYSE American

MENLO PARK, Calif., Sept. 28, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company developing products for the dermatology market, received a notice on September 24, 2018 from the NYSE American LLC (the "NYSE American") that...

BioPharmX Corporation Announces David S. Tierney, M.D. Joined the Company as Chief Executive Officer

MENLO PARK, Calif., Sept. 12, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced the appointment of David S. Tierney, M.D., as its chief executive officer. Anja Krammer...
Show more
Report incorrect company information

BioPharmX Blogs

BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular Rosacea

Company anticipates announcing topline efficacy and safety results in July 2019

BioPharmX Strengthens Board of Directors with Appointment of Industry Veteran Dr. R. Todd Plott

Dr. R. Todd Plott, developer of SOLODYN™, ZIANA™, and NORITATE™, becomes company's third independent director

BioPharmX Initiates Phase 2b Trial of BPX-04 for Rosacea

Trial will evaluate 1% concentration of minocycline carried by company's patented HyantX™ delivery system

BioPharmX Receives IRB Approval to Initiate Phase 2 Trial of BPX-04 for the Treatment of Rosacea

Open-label feasibility study results identify BPX-04 topical minocycline gel, 1% as optimal dose for phase 2 trial
Show more

BioPharmX Frequently Asked Questions

  • When was BioPharmX founded?

    BioPharmX was founded in 2011.

  • How many employees does BioPharmX have?

    BioPharmX has 27 employees.

  • What is BioPharmX revenue?

    Latest BioPharmX annual revenue is $57 k.

  • What is BioPharmX revenue per employee?

    Latest BioPharmX revenue per employee is $2.1 k.

  • Who are BioPharmX competitors?

    Competitors of BioPharmX include Repros Therapeutics, Clinipace Worldwide and TherapeuticsMD.

  • Where is BioPharmX headquarters?

    BioPharmX headquarters is located at 1505 Adams Dr, Menlo Park.

  • Where are BioPharmX offices?

    BioPharmX has an office in Menlo Park.

  • How many offices does BioPharmX have?

    BioPharmX has 1 office.